Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan
· Delayed Price · Currency is TWD 15.60
-0.65 (-4.00%)
Mar 10, 2026, 1:07 PM CST
Meribank Biotech Revenue
Meribank Biotech had revenue of 250.42M TWD in the half year ending June 30, 2025, with 142.98% growth. This brings the company's revenue in the last twelve months to 486.52M, up 85.97% year-over-year. In the year 2024, Meribank Biotech had annual revenue of 366.43M with 56.37% growth.
Revenue (ttm)
486.52M
Revenue Growth
+85.97%
P/S Ratio
2.94
Revenue / Employee
3.43M
Employees
142
Market Cap
1.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 366.43M | 132.09M | 56.37% |
| Dec 31, 2023 | 234.34M | 54.22M | 30.10% |
| Dec 31, 2022 | 180.12M | 17.04M | 10.45% |
| Dec 31, 2021 | 163.08M | -31.32M | -16.11% |
| Dec 31, 2020 | 194.39M | 33.44M | 20.78% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Abnova (Taiwan) | 351.30M |
| Great Novel Therapeutics Biotech & Medicals | 1.78M |
| NeoCore Technology | 190.10M |
| GenMont Biotech Incorporation | 391.48M |
| Enimmune | 42.23M |
| Genomics BioSci & Tech. | 607.89M |
| GeneReach Biotechnology | 215.32M |
| Anti-Microbial Savior BioteQ | 612.00K |